Sanoj Punnen, MD, MAS, presented “Integrating MRI and Molecular Markers to Detect Aggressive Prostate Cancer” during the 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 3, 2019 in Boston, Massachusetts.
How to cite: Punnen, Sanoj. “Integrating MRI and Molecular Markers to Detect Aggressive Prostate Cancer” October 3, 2019. Accessed Nov 2024. https://grandroundsinurology.com/integrating-mri-and-molecular-markers-to-detect-aggressive-prostate-cancer/
Integrating MRI and Molecular Markers to Detect Aggressive Prostate Cancer – Summary:
Sanoj Punnen, MD, MAS, Associate Professor of Clinical Urology in the University of Miami Health System, describes how recent trial based research has supported the synergistic qualities of MRI and biomarkers in the cancer detection process by reducing unnecessary biopsies by approximately 25%. He notes that more research is needed to declare an ideal procedure as well as what biomarkers are most efficient. Introducing MRI reading AI by the name Habitat Risk Scoring System, he highlights his own research which could alter how MRIs are processed and increase NPV to 92% without the use of biopsy.
About The 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer:
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a multi-day, multi-disciplinary forum designated to informing health care stakeholders about topics including in-vitro fluid- and tissue-based molecular diagnostics, novel observation strategies such as active surveillance, and novel therapeutic interventions. Along with this forum’s efforts to form a consensus on the future of prostate diagnostics and precision care, it aims to create an educational and research strategy for its realization. Dr. Punnen presented this lecture during the 4th iteration of this Summit in 2019.
For more educational content from this meeting, please visit our collection page.
ABOUT THE AUTHOR
Sanoj Punnen, MD, MAS, completed his medical school at Queen’s University and urology residency at the University of Toronto in Canada. He then completed a uro-oncology fellowship and Master’s in Clinical Research at the University of California, San Francisco. He is board-certified in both urology and uro-oncology. His primary research interest is in localized prostate cancer. Specifically, his work has evaluated imaging, molecular, and genomic markers that play a role in prostate cancer diagnosis and prognosis. He is also involved in outcomes and health service research on trends in the incidence and management of prostate cancer.
